Update Management of Chemotherapy-Induced Neutropenia: A Narrative Literature Review
DOI:
https://doi.org/10.37275/bsm.v7i1.764Keywords:
Antibiotic, Antifungal, Chemotherapy, Granulocyte stimulating factors, NeutropeniaAbstract
One of the most frequent and significant complicated side effects of myelosuppressive drugs is neutropenia. Neutropenia is not only associated with high morbidity but also mortality. Generally, the onset of neutropenia occurs within 3-7 days after the administration of anticancer agents. Approximately 5-30% of patients will develop febrile neutropenia. The highest incidence occurs during the first cycle of chemotherapy. This literature review aimed to describe chemotherapy-induced neutropenia and its prevention and management. Administration of granulocyte colony-stimulating factor as prophylaxis can prevent neutropenia-induced anticancer drugs. The use of granulocyte colony-stimulating factor (G-CSF) as therapeutic is contradictive, and some guidelines recommend not to use the G-CSF for therapeutic purposes. Up to 70% of mortality among these populations was associated with gram-negative sepsis, therefor empirical antibiotics, and antifungals are the keys to the management of neutropenia. In conclusion, prevention and appropriate management of neutropenia are extremely important in the treatment of patients with cancer.
Authors
- Mita Adriani1*
- Mediarty Syahrir2
- Yenny Dian Andayani2
- Norman Djamaluddin2
- 1Subspecialized Residency Training, Division of Hematology and Medical Oncology, Department of Internal Medicine, Universitas Sriwijaya, Palembang, Indonesia
- 2Consultant, Division of Hematology and Medical Oncology, Department of Internal Medicine, Universitas Sriwijaya, Palembang, Indonesia
Corresponding author Mita Adriani — dr.mitaadriani@yahoo.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
